JP2023533772A - ＳＡＲＳ－ＣｏＶ－２及びインフルエンザ混合ワクチン - Google Patents

ＳＡＲＳ－ＣｏＶ－２及びインフルエンザ混合ワクチン Download PDF

Info

Publication number
JP2023533772A
JP2023533772A JP2023501632A JP2023501632A JP2023533772A JP 2023533772 A JP2023533772 A JP 2023533772A JP 2023501632 A JP2023501632 A JP 2023501632A JP 2023501632 A JP2023501632 A JP 2023501632A JP 2023533772 A JP2023533772 A JP 2023533772A
Authority
JP
Japan
Prior art keywords
influenza
cov
sars
covid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023501632A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022009121A5 (enExample
Inventor
ラインハルト グルック
アガタ ファジオ
エマニュエル モントモリ
カスパー バンジジャー
カルロス クイント
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spicona Inc
Original Assignee
Spicona Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spicona Inc filed Critical Spicona Inc
Publication of JP2023533772A publication Critical patent/JP2023533772A/ja
Publication of JPWO2022009121A5 publication Critical patent/JPWO2022009121A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023501632A 2020-07-07 2021-07-07 ＳＡＲＳ－ＣｏＶ－２及びインフルエンザ混合ワクチン Pending JP2023533772A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2010425.3A GB2596820A (en) 2020-07-07 2020-07-07 Combination vaccine
GB2010425.3 2020-07-07
PCT/IB2021/056102 WO2022009121A1 (en) 2020-07-07 2021-07-07 Sars-cov-2 and influenza combination vaccine

Publications (2)

Publication Number Publication Date
JP2023533772A true JP2023533772A (ja) 2023-08-04
JPWO2022009121A5 JPWO2022009121A5 (enExample) 2024-07-16

Family

ID=72050416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501632A Pending JP2023533772A (ja) 2020-07-07 2021-07-07 ＳＡＲＳ－ＣｏＶ－２及びインフルエンザ混合ワクチン

Country Status (15)

Country Link
US (1) US20230256085A1 (enExample)
EP (1) EP4178612A1 (enExample)
JP (1) JP2023533772A (enExample)
KR (1) KR20230049084A (enExample)
CN (1) CN117957016A (enExample)
AR (1) AR122899A1 (enExample)
AU (1) AU2021303789A1 (enExample)
BR (1) BR112023000323A2 (enExample)
CA (1) CA3184878A1 (enExample)
CO (1) CO2023001072A2 (enExample)
GB (1) GB2596820A (enExample)
IL (1) IL299735A (enExample)
MX (1) MX2023000411A (enExample)
TW (1) TW202207979A (enExample)
WO (1) WO2022009121A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. INFLUENZA VACCINE
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2021213924A1 (en) 2020-04-22 2021-10-28 BioNTech SE Coronavirus vaccine
CN113980140B (zh) * 2020-10-23 2024-06-25 江苏省疾病预防控制中心(江苏省公共卫生研究院) 融合蛋白及其应用
CN113293145B (zh) * 2021-02-01 2022-08-26 上海青赛生物科技有限公司 一种麻疹病毒活载体新冠疫苗
EP4322994A1 (en) * 2021-04-14 2024-02-21 ModernaTX, Inc. Influenza-coronavirus combination vaccines
CN113462700B (zh) * 2021-05-07 2023-06-09 杨光华 SARS-CoV-2线性DNA疫苗
CN114717251B (zh) * 2021-08-24 2023-03-24 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2原始株和Beta株的腺病毒载体疫苗
US20240398930A1 (en) * 2021-09-24 2024-12-05 Bharat Biotech International Limited A vaccine for coronavirus and influenza virus, and method for preparation thereof
CN113755644B (zh) * 2021-09-24 2024-05-03 中国科学院武汉病毒研究所 一种检测新型冠状病毒Alpha和Delta突变体试剂盒及应用
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CN114891817A (zh) * 2022-04-15 2022-08-12 华南理工大学 一种多聚肽及其制备方法与应用
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024174012A1 (pt) * 2023-02-24 2024-08-29 Instituto Butantan Composição imunogênica, uso da mesma e processo de obtenção de uma composição imunogênica combinada contra covid-19 e influenza sazonal
CN115992101B (zh) * 2023-03-22 2023-07-28 深圳市卫光生物制品股份有限公司 一种流感病毒裂解疫苗原液的制备方法
CN116327910B (zh) * 2023-03-31 2024-05-03 北京吉诺卫生物科技有限公司 一种新冠病毒、流感病毒和/或rsv的联合疫苗、其制备方法与应用
CN116350769B (zh) * 2023-03-31 2024-07-19 北京吉诺卫生物科技有限公司 一种新冠病毒和流感病毒的联合疫苗、其制备方法与应用
WO2024232415A1 (ja) * 2023-05-10 2024-11-14 国立大学法人北海道大学 インフルエンザ及びコロナウイルス感染症予防のための混合ワクチン
CN118141906B (zh) * 2024-02-22 2025-08-22 安徽智飞龙科马生物制药有限公司 一种新冠流感联合疫苗及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014504634A (ja) * 2011-02-04 2014-02-24 ゾエティス・エルエルシー イヌ呼吸器病症候群のための組成物
CN111217917A (zh) * 2020-02-26 2020-06-02 康希诺生物股份公司 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
CN1775287A (zh) * 2004-11-16 2006-05-24 北京科兴生物制品有限公司 一种sars流感二价联合疫苗及其制备工艺
GB0822001D0 (en) * 2008-12-02 2009-01-07 Glaxosmithkline Biolog Sa Vaccine
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
US20130236494A1 (en) * 2012-03-06 2013-09-12 Crucell Holland B.V. Vaccination against influenza
CN107961371B (zh) * 2017-04-19 2020-08-11 武汉博沃生物科技有限公司 季节流感-rsv联合疫苗及其制备方法和应用
CN110974950B (zh) * 2020-03-05 2020-08-07 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
CN111218458B (zh) * 2020-02-27 2020-11-20 珠海丽凡达生物技术有限公司 编码SARS-CoV-2病毒抗原的mRNA和疫苗及疫苗的制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014504634A (ja) * 2011-02-04 2014-02-24 ゾエティス・エルエルシー イヌ呼吸器病症候群のための組成物
CN111217917A (zh) * 2020-02-26 2020-06-02 康希诺生物股份公司 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUMAN VACCINES & IMMUNOTHERAPEUTICS, vol. 14, no. 2, JPN6025024385, 2018, pages 378 - 385, ISSN: 0005617929 *

Also Published As

Publication number Publication date
AR122899A1 (es) 2022-10-12
AU2021303789A1 (en) 2023-02-16
WO2022009121A1 (en) 2022-01-13
EP4178612A1 (en) 2023-05-17
CO2023001072A2 (es) 2023-06-20
CN117957016A (zh) 2024-04-30
GB202010425D0 (en) 2020-08-19
GB2596820A (en) 2022-01-12
BR112023000323A2 (pt) 2023-01-31
TW202207979A (zh) 2022-03-01
US20230256085A1 (en) 2023-08-17
KR20230049084A (ko) 2023-04-12
IL299735A (en) 2023-03-01
CA3184878A1 (en) 2022-01-13
MX2023000411A (es) 2023-04-10

Similar Documents

Publication Publication Date Title
JP2023533772A (ja) ＳＡＲＳ－ＣｏＶ－２及びインフルエンザ混合ワクチン
Mezhenskaya et al. M2e-based universal influenza vaccines: a historical overview and new approaches to development
US20240108715A1 (en) 2019-ncov (sars-cov-2) vaccine
KR101983989B1 (ko) 인플루엔자 바이러스 백신 및 이의 용도
AU2022204267A1 (en) Vaccine compositions
AU2010303568B2 (en) Immunopotentiator-linked oligomeric influenza immunogenic compositions
CN105452270B (zh) 流行性感冒病毒疫苗及其用途
US9683020B2 (en) VLPS containing ligands and methods related thereto
EP3541419B1 (en) Immunogenic composition for mers coronavirus infection
JP2018535251A (ja) ブタサーコウイルス３型免疫原性組成物、その製造方法、およびその使用方法
US11103575B2 (en) Immunogenic composition for MERS coronavirus infection
US20070286873A1 (en) Recombinant Influenza H5 Hemagluttinin Protein And Nucleic Acid Coding Therefor
WO2021178623A1 (en) Immunogenic compositions against severe acute respiratory syndrome coronavirus 2
JP2023519837A (ja) コロナウイルスを処置するためのワクチン組成物
US20170290906A1 (en) VLPS Containing Ligands and Methods Related Thereto
CN105085671B (zh) 抗肠道病毒3d蛋白的单克隆免疫球蛋白g抗体及其免疫原性组合物
CA2904382A1 (en) Enhanced expression of picornavirus proteins
WO2016115665A1 (en) Immunoglobulin g monoclonal antibodies against 3d proteins of enteroviruses
WO2016115664A1 (en) 3d protein-specific monoclonal immunoglobulin a antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251215